FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171139682> ?p ?o ?g. }

• W2171139682 endingPage "97" @default.
• W2171139682 startingPage "93" @default.
• W2171139682 abstract "Concurrent chemoradiotherapy is the standard treatment for unresectable stage III non-small cell lung cancer (NSCLC). The long-term feasibility and efficacy of vinorelbine and cisplatin with concurrent thoracic radiotherapy were investigated. Eighteen patients received cisplatin (80 mg/m2) on day 1 and vinorelbine (20 mg/m2 in level 1, and 25 mg/m2 in level 2) on days 1 and 8 every 4 weeks for four cycles in a phase I trial. Ninety-three patients received the same chemotherapy regimen except for the fixed vinorelbine (20 mg/m2) dosage and consolidation therapy with docetaxel (60 mg/m2, every 3 weeks). The thoracic radiotherapy consisted of a single dose of 2 Gy once daily to a total dose of 60 Gy. A total of 111 patients were analyzed in the present study: male/female, 91/20; median age, 60 years; stage IIIA/IIIB, 50/61; and squamous/non-squamous histology, 26/85. The 3-, 5-, and 7-year overall survival rates (95% CI) were 43.2% (33.9–52.2), 25.2% (17.6–33.5), and 23.2% (15.8–31.4), respectively. The median progression-free survival and median survival time (95% CI) were 13.5 (10.1–16.7) months and 30.0 (24.3–38.8) months, respectively. Four patients (4%) experienced Grade 5 pulmonary toxicities from 4.4 to 9.4 months after the start of treatment. In conclusion, approximately 15% of patients with unresectable stage III NSCLC could be cured with chemoradiotherapy without severe late toxicities after 10 months of follow-up. Although based on the data from highly selected population participated in phase I and phase II trial, this analysis would strengthen and confirm the previous reports concerning concurrent chemoradiotherapy with third generation cytotoxic agents. (Cancer Sci 2013; 104: 93–97)" @default.
• W2171139682 created "2016-06-24" @default.
• W2171139682 creator A5035375326 @default.
• W2171139682 creator A5037461196 @default.
• W2171139682 creator A5050855780 @default.
• W2171139682 creator A5054539545 @default.
• W2171139682 creator A5055518358 @default.
• W2171139682 creator A5060063956 @default.
• W2171139682 creator A5069589468 @default.
• W2171139682 date "2012-11-08" @default.
• W2171139682 modified "2023-10-17" @default.
• W2171139682 title "Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer" @default.
• W2171139682 cites W1944220675 @default.
• W2171139682 cites W1969703712 @default.
• W2171139682 cites W1980918705 @default.
• W2171139682 cites W1993312546 @default.
• W2171139682 cites W2021162833 @default.
• W2171139682 cites W2023291932 @default.
• W2171139682 cites W2036094938 @default.
• W2171139682 cites W2044191519 @default.
• W2171139682 cites W2062668422 @default.
• W2171139682 cites W2082687472 @default.
• W2171139682 cites W2087680614 @default.
• W2171139682 cites W2093760924 @default.
• W2171139682 cites W2105024669 @default.
• W2171139682 cites W2105969273 @default.
• W2171139682 cites W2108215214 @default.
• W2171139682 cites W2109950864 @default.
• W2171139682 cites W2110590052 @default.
• W2171139682 cites W2115774764 @default.
• W2171139682 cites W2129675268 @default.
• W2171139682 cites W2139248078 @default.
• W2171139682 cites W2140469315 @default.
• W2171139682 cites W2160433100 @default.
• W2171139682 cites W2160797118 @default.
• W2171139682 cites W2167661968 @default.
• W2171139682 cites W4240275310 @default.
• W2171139682 cites W4241174054 @default.
• W2171139682 cites W4249467884 @default.
• W2171139682 doi "https://doi.org/10.1111/cas.12028" @default.
• W2171139682 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7657241" @default.
• W2171139682 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23004347" @default.
• W2171139682 hasPublicationYear "2012" @default.
• W2171139682 type Work @default.
• W2171139682 sameAs 2171139682 @default.
• W2171139682 citedByCount "31" @default.
• W2171139682 countsByYear W21711396822013 @default.
• W2171139682 countsByYear W21711396822014 @default.
• W2171139682 countsByYear W21711396822015 @default.
• W2171139682 countsByYear W21711396822016 @default.
• W2171139682 countsByYear W21711396822017 @default.
• W2171139682 countsByYear W21711396822018 @default.
• W2171139682 countsByYear W21711396822019 @default.
• W2171139682 countsByYear W21711396822020 @default.
• W2171139682 countsByYear W21711396822021 @default.
• W2171139682 countsByYear W21711396822022 @default.
• W2171139682 countsByYear W21711396822023 @default.
• W2171139682 crossrefType "journal-article" @default.
• W2171139682 hasAuthorship W2171139682A5035375326 @default.
• W2171139682 hasAuthorship W2171139682A5037461196 @default.
• W2171139682 hasAuthorship W2171139682A5050855780 @default.
• W2171139682 hasAuthorship W2171139682A5054539545 @default.
• W2171139682 hasAuthorship W2171139682A5055518358 @default.
• W2171139682 hasAuthorship W2171139682A5060063956 @default.
• W2171139682 hasAuthorship W2171139682A5069589468 @default.
• W2171139682 hasBestOaLocation W21711396821 @default.
• W2171139682 hasConcept C126322002 @default.
• W2171139682 hasConcept C141071460 @default.
• W2171139682 hasConcept C143998085 @default.
• W2171139682 hasConcept C146357865 @default.
• W2171139682 hasConcept C151730666 @default.
• W2171139682 hasConcept C2776256026 @default.
• W2171139682 hasConcept C2776694085 @default.
• W2171139682 hasConcept C2778239845 @default.
• W2171139682 hasConcept C2778424827 @default.
• W2171139682 hasConcept C2780350996 @default.
• W2171139682 hasConcept C2781190966 @default.
• W2171139682 hasConcept C2781413609 @default.
• W2171139682 hasConcept C509974204 @default.
• W2171139682 hasConcept C71924100 @default.
• W2171139682 hasConcept C86803240 @default.
• W2171139682 hasConcept C90924648 @default.
• W2171139682 hasConceptScore W2171139682C126322002 @default.
• W2171139682 hasConceptScore W2171139682C141071460 @default.
• W2171139682 hasConceptScore W2171139682C143998085 @default.
• W2171139682 hasConceptScore W2171139682C146357865 @default.
• W2171139682 hasConceptScore W2171139682C151730666 @default.
• W2171139682 hasConceptScore W2171139682C2776256026 @default.
• W2171139682 hasConceptScore W2171139682C2776694085 @default.
• W2171139682 hasConceptScore W2171139682C2778239845 @default.
• W2171139682 hasConceptScore W2171139682C2778424827 @default.
• W2171139682 hasConceptScore W2171139682C2780350996 @default.
• W2171139682 hasConceptScore W2171139682C2781190966 @default.
• W2171139682 hasConceptScore W2171139682C2781413609 @default.
• W2171139682 hasConceptScore W2171139682C509974204 @default.
• W2171139682 hasConceptScore W2171139682C71924100 @default.
• W2171139682 hasConceptScore W2171139682C86803240 @default.
• W2171139682 hasConceptScore W2171139682C90924648 @default.

• next